Who are Wobe-Mugos E's main competitors?

Direct comparators (same drug class / molecular target / therapeutic area): Test formulation (Treatment A), Elfabrio, Neogaa, Asparlas, Asparlas, PEGVALIASE.

How often does this brief refresh?

Every 30 minutes from primary sources (FDA, EMA, MHRA, PMDA, ClinicalTrials.gov, USPTO). Subscribe to the RSS feed below for push alerts.

How do I get this as a recurring report?

Subscribe to /feed/ci/wobe-mugos-e.xml in any RSS reader (Feedly, Inoreader, NewsBlur). Every regulatory action, trial readout, or patent event lands in your feed automatically.

Last reviewed 2026-05-13 · How we verify

Wobe-Mugos E — Competitive Intelligence Brief

Wobe-Mugos E (Wobe-Mugos E) competitive landscape: 6 comparators, recent regulatory actions, upcoming PDUFA, patent timeline. Class: Enzyme. Area: Respiratory.

phase 3 Enzyme Deoxyribonuclease, Ribonuclease inhibitor Respiratory Small molecule Live · refreshed every 30 min

Target snapshot

Wobe-Mugos E (Wobe-Mugos E) — Medsearch. Wobe-Mugos E is a combination of a deoxyribonuclease and a ribonuclease inhibitor.

Comparator set (6 drugs)

Auto-detected by same drug class / molecular target / therapeutic area, ranked by phase + recency. Override with ?vs=slug1,slug2,….

Drug	Generic	Sponsor	Phase	Class	Target	Approval / PDUFA
Wobe-Mugos E TARGET	Wobe-Mugos E	Medsearch	phase 3	Enzyme	Deoxyribonuclease, Ribonuclease inhibitor
Test formulation (Treatment A)	test-formulation-treatment-a	Pfizer	marketed	Enzyme inhibitor	Specific enzyme	Not yet determined
Elfabrio	PEGUNIGALSIDASE ALFA	Chiesi Farmaceutici S.P.A	marketed	Hydrolytic Lysosomal Neutral Glycosphingolipid-specific Enzyme [EPC]		2023-01-01
Neogaa	AVALGLUCOSIDASE ALFA	Sanofi	marketed	Hydrolytic Lysosomal Glycogen-specific Enzyme [EPC]		2021-01-01
Asparlas	CALASPARGASE PEGOL	Servier Pharma Llc	marketed	Asparagine-specific Enzyme [EPC]		2018-01-01
Asparlas	calaspargase	Pfizer	marketed	Asparagine-specific Enzyme [EPC]	L-asparagine	2018-01-01
PEGVALIASE	PEGVALIASE		marketed	Phenylalanine Metabolizing Enzyme [EPC]	phenylalanine	2018-01-01

Recent regulatory actions (last 90 days)

No regulatory actions in the last 90 days for this set.

Upcoming PDUFA dates (next 180 days)

No PDUFA dates in the next 180 days for this set.

Patent timeline (forward window)

No upcoming patent expiries for this set.

Sponsor landscape (Enzyme class)

Andrew E. Place, MD · 1 drug in this class
Dana-Farber Cancer Institute · 1 drug in this class
Medsearch · 1 drug in this class
medac GmbH · 1 drug in this class

Subscribe to ongoing alerts

Push every new event for this competitive set into your RSS reader, IFTTT/Zapier workflow, or email digest:

Cite this brief

Drug Landscape (2026). Wobe-Mugos E — Competitive Intelligence Brief. https://druglandscape.com/ci/wobe-mugos-e. Accessed 2026-05-13.

Build your own brief

Pick any drug + add comparators:

https://druglandscape.com/ci/{slug} — auto-detected competitors
https://druglandscape.com/ci/{slug}?vs=drug1,drug2,drug3 — explicit comparators
Brand names auto-resolve: /ci/keytruda → 301 → /ci/pembrolizumab